Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR) has also shown great potential in this field. Here, Nikki Withers speaks to Miguel Forte who elaborates on the process…
List view / Grid view
Filter the results
Your vision is to create revolutionary cell and gene therapies to treat life threatening diseases. Bio-Techne and its family of brands is on this journey with you.
A novel therapy, tested ex vivo, has been successful at correcting the dysfunctional body mechanism in Postural Orthostatic Tachycardia Syndrome (POTS).
A new population of stem cells that can generate bone has been revealed by researchers, which they say could have implications in regenerative medicine.
23 May 2019 | By Sartorius
Join us as we discuss the promises and pitfalls associated with developing individualised antigen-specific T-cell therapy products for clinical use.
27 April 2018 | By Mitra Biotech
In this webinar, speaker Mark Paris, PhD discussed a recent study evaluating a cohort of HNSCC patient tumours treated with anti-PD1 using CANscript TM;. He also be reviewed the results of this study as a means of investigating predictors of clinical response and identifying mechanisms of resistance.
Researchers in America have demonstrated the feasibility of their ‘placenta-on-a-chip’ platform in studying how drugs are transported across the human placental barrier.
6 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Foster City will serve as headquarters for Orchard Therapeutics North America, and will provide the central base for laboratory operations associated...